OKYO News

There was just one small IPO and one direct listing this past week. Although there were no new IPO filings, a few large deals in the pipeline updated their prospectuses, including Corebridge Financial (CRBG), Turo (TURO) Fogo Hospitality (FOGO), and Claire’s (CLRS). After delaying the previous week,...read more

Companies have broadly put listing plans on hold amid the worst IPO sell-off in over a decade, but small issuers are still on the move. So far, 21 of the year’s 34 IPOs (62%) have raised less than $50 million, the highest concentration in over a decade. Sub-$50 million IPOs have historically accounted for less than one-quarter of activity. Small issuers are on track to...read more

OKYO Pharma, a preclinical biotech developing a lipidated chemerin peptide for dry eye disease, raised $2.5 million by offering 0.6 million ADSs at $4.00, below the as-converted $4.60 last close of its shares on the LSE (symbol: OKYO). At the offer price, OKYO Pharma commands a market value of $87 million. The company originally filed in April 2022 to raise $10 million, before twice...read more

OKYO Pharma, a preclinical biotech developing a lipidated chemerin analog for dry eye disease, lowered the proposed deal size for its upcoming IPO on Friday. The St. Peter Port, Guernsey-based company now plans to raise $3 million by offering 0.5 million ADSs at a price of $4.92, the as-converted last close of its shares on the LSE (OKYO). The company had most recently filed in...read more